MX2024010693A - Proteina de fusion de insulina - Google Patents

Proteina de fusion de insulina

Info

Publication number
MX2024010693A
MX2024010693A MX2024010693A MX2024010693A MX2024010693A MX 2024010693 A MX2024010693 A MX 2024010693A MX 2024010693 A MX2024010693 A MX 2024010693A MX 2024010693 A MX2024010693 A MX 2024010693A MX 2024010693 A MX2024010693 A MX 2024010693A
Authority
MX
Mexico
Prior art keywords
fusion protein
insulin fusion
insulin
canine
feline
Prior art date
Application number
MX2024010693A
Other languages
English (en)
Spanish (es)
Inventor
Samantha J Busfield
Matthew J Wilson
Original Assignee
Scout Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scout Bio Inc filed Critical Scout Bio Inc
Publication of MX2024010693A publication Critical patent/MX2024010693A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2024010693A 2022-03-01 2024-08-30 Proteina de fusion de insulina MX2024010693A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263315296P 2022-03-01 2022-03-01
PCT/US2023/063510 WO2023168288A2 (en) 2022-03-01 2023-03-01 Insulin fusion protein

Publications (1)

Publication Number Publication Date
MX2024010693A true MX2024010693A (es) 2024-12-06

Family

ID=87884362

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010693A MX2024010693A (es) 2022-03-01 2024-08-30 Proteina de fusion de insulina

Country Status (11)

Country Link
US (1) US20250188144A1 (https=)
EP (1) EP4486796A4 (https=)
JP (1) JP2025507929A (https=)
KR (1) KR20240167718A (https=)
CN (1) CN119562965A (https=)
AU (1) AU2023228668A1 (https=)
CA (1) CA3245376A1 (https=)
CL (1) CL2024002605A1 (https=)
IL (1) IL315354A (https=)
MX (1) MX2024010693A (https=)
WO (1) WO2023168288A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120173090B (zh) * 2025-05-21 2025-07-29 华中农业大学 猫血清白蛋白突变体、及其cho细胞表达方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002364586A1 (en) * 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US9505823B2 (en) * 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
CA2676932C (en) * 2007-02-01 2015-11-24 Technion Research & Development Foundation Ltd. Albumin fibers and fabrics and methods of generating and using same
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
BR112014015156A2 (pt) * 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
WO2022098906A1 (en) * 2020-11-04 2022-05-12 The Trustees Of The University Of Pennsylvania Viral vectors encoding canine insulin for treatment of metabolic diseases in dogs
AU2023228669A1 (en) * 2022-03-01 2024-09-19 Scout Bio, Inc. Viral vector genome encoding an insulin fusion protein

Also Published As

Publication number Publication date
JP2025507929A (ja) 2025-03-21
CA3245376A1 (en) 2023-09-07
US20250188144A1 (en) 2025-06-12
KR20240167718A (ko) 2024-11-27
WO2023168288A2 (en) 2023-09-07
AU2023228668A1 (en) 2024-09-19
WO2023168288A3 (en) 2023-09-28
EP4486796A4 (en) 2026-03-04
IL315354A (en) 2024-11-01
CN119562965A (zh) 2025-03-04
EP4486796A2 (en) 2025-01-08
CL2024002605A1 (es) 2025-07-11

Similar Documents

Publication Publication Date Title
MX2024010693A (es) Proteina de fusion de insulina
JP2014159431A (ja) 血糖降下剤の投与方法
Airaghi et al. The insulin analog aspart: a safe alternative in insulin allergy
PE20121362A1 (es) Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
BRPI0518460A2 (pt) mÉtodo para tratar emergÊncia alÉrgica em um paciente, dispositivo de distribuiÇço de droga contendo uma soluÇço de epinefrina, e, kit para tratar uma emergÊncia alÉrgia'
DE602004012745D1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
MX2024010711A (es) Genoma de vector viral que codifica una proteína de fusión de insulina
TW200833367A (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals
MX2012006568A (es) Analogos de insulina con aminoacidos clorados.
ECSP23024034A (es) Métodos para reducir el contenido de proteínas de la célula huésped en procesos de purificación de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteínas de la célula huésped
ATE495753T1 (de) Zusammensetzung zur transmukosalen abgabe von polypeptiden
SE0402507D0 (sv) Medicinsk lösning, förfarande för framställning och användning därav
Malone et al. Eli Lilly and Company insulins—a century of innovation
AR050673A1 (es) Composicion farmaceutica compuesta por toxina botulinica para el tratamiento del dolor en la articulacion de la rodilla por compresion del nervio safeno
TW200735781A (en) Food product
RU2006106836A (ru) Способ лечения экспериментального туберкулеза у животных
Das et al. Carbimazole-induced agranulocytosis treated with propylthiouracil
EA200800729A1 (ru) Лечение неврита зрительного нерва
US20210213104A1 (en) Glucagon and glp-1 co-agonists for the treatment of chronic kidney disease and diabetic kidney disease in type 2 diabetes
Dieuzeide Symposium: New horizons in the treatment of type 1 diabetes mellitus. New insulins. Smart insulin
MX2022009492A (es) Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de factor de von willebrand (fvw) recombinante.
AR095625A1 (es) Albúmina humana recombinante-factor estimulante de colonia de granulocitos humano para la prevención de neutropenia en pacientes pediátricos
Hess Which insulin and which dosing regimen in 2006?
CA3308945A1 (en) Methods and techniques for treating facial assymetry by administering dermal injections to patients based upon facial asymmetry
TW200727928A (en) Method and apparatus for delivering epinephrine